Ocular Surface Metabolo-lipidomics in Lateral Amyotrophic Sclerosis

NCT04953286 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2025-12-22

No results posted yet for this study

Summary

Amyotrophic Lateral Sclerosis (ALS) is the most common neurodegenerative disease affecting the motor neuron. Currently, there is no diagnostic test and no examination that can predict the evolution of this pathology. The search for diagnostic and prognostic biomarkers is therefore essential for a better understanding of the pathophysiology of ALS, which remains poorly understood, and also for better clinical management. The ocular surface, made up of liquid elements, tears, and cells, is an accessible anatomical-physiological entity that has demonstrated its usefulness in the identification of biomarkers in neurodegenerative diseases such as Parkinson's or Alzheimer's. To date, no study has explored the ocular surface as a biomarker in ALS

Conditions

Interventions

OTHER

Evaluation of the corneal innervation

Contact corneal confocal microscopy

OTHER

Slit lamp examination and undilated fundus

Slit lamp examination and undilated fundus

OTHER

Conjunctival impression

Conjunctival impression with anesthetic instillation

OTHER

Samples of basal tears

Collection of basal tears without instillation of anesthetic with a Schirmer strip for 5 minutes and by microcapillary

OTHER

Central corneal sensitivity

Central corneal sensitivity using a Cochet-Bonnet esthesiometer (Luneau©)

OTHER

Measure of visual acuity

ETDRS and Parinaud scale

OTHER

Interferometry

Non-contact exam measuring N.I.B.U.T (Non-invasive break-up time), quantitative and qualitative evaluation of the meibomian glands and quantitative evaluation of the tear meniscus

Sponsors & Collaborators

  • University Hospital, Tours

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-17
Primary Completion
2023-09-30
Completion
2023-09-30

Countries

  • France

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04953286 on ClinicalTrials.gov